Debrisoquine

Identification

Generic Name

Debrisoquine

DrugBank Accession Number

DB04840

Background

An adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.

Type

Small Molecule

Groups

Approved, Investigational

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Debrisoquine (DB04840)

×

Close

Weight

Average: 175.2303
Monoisotopic: 175.110947431

Chemical Formula

C₁₀H₁₃N₃

Synonyms

• Debrisochinum
• Debrisoquin
• Debrisoquina
• Debrisoquine
• Débrisoquine
• Debrisoquinum

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

For the treatment of moderate and severe hypertension, either alone or as an adjunct, and for the treatment of renal hypertension.

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Debrisoquin is an adrenergic neuron-blocking drug similar in effects to guanethidine. It is a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.

Mechanism of action

Debrisoquin acts at the sympathetic neuroeffector junction by inhibiting or interfering with the release and/or distribution of norepinephrine, rather than acting at the effector cell by inhibiting the association of norepinephrine with its receptors. It is taken up by norepinephrine transporters. It becomes concentrated in NE transmitter vesicles, replacing NE in these vesicles. This leads to a gradual depletion of NE stores in the nerve endings. Once inside the terminal it blocks the release of noradrenaline in response to arrival of an action potential. In contrast to ganglionic blocking agents, debrisoquin suppresses equally the responses mediated by alpha-and beta-adrenergic receptors but does not produce parasympathetic blockade. Since sympathetic blockade results in modest decreases in peripheral resistance and cardiac output, debrisoquin lowers blood pressure in the supine position. It further reduces blood pressure by decreasing the degree of vasoconstriction that normally results from reflex sympathetic nervous activity upon assumption of the upright posture, thus reducing venous return and cardiac output more.

Target	Actions	Organism
ASodium-dependent noradrenaline transporter	inducer	Humans

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Hepatic.

Hover over products below to view reaction partners

• Debrisoquine
  • 4-Hydroxydebrisoquine

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Abaloparatide	Abaloparatide may increase the hypotensive activities of Debrisoquine.
Abatacept	The metabolism of Debrisoquine can be increased when combined with Abatacept.
Abiraterone	The metabolism of Debrisoquine can be decreased when combined with Abiraterone.
Acebutolol	The metabolism of Debrisoquine can be decreased when combined with Acebutolol.
Aceclofenac	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Aceclofenac.
Acemetacin	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Acemetacin.
Acetaminophen	The metabolism of Debrisoquine can be decreased when combined with Acetaminophen.
Acetylsalicylic acid	Acetylsalicylic acid may decrease the antihypertensive activities of Debrisoquine.
Adagrasib	The metabolism of Debrisoquine can be decreased when combined with Adagrasib.
Adalimumab	The metabolism of Debrisoquine can be increased when combined with Adalimumab.
Albuterol	Salbutamol may decrease the antihypertensive activities of Debrisoquine.
Alclofenac	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Alclofenac.
Aldesleukin	Aldesleukin may increase the hypotensive activities of Debrisoquine.
Alfentanil	Alfentanil may decrease the antihypertensive activities of Debrisoquine.
Alfuzosin	Alfuzosin may increase the hypotensive activities of Debrisoquine.
Aliskiren	Debrisoquine may increase the hypotensive activities of Aliskiren.
Almotriptan	Almotriptan may decrease the antihypertensive activities of Debrisoquine.
Alogliptin	The metabolism of Alogliptin can be decreased when combined with Debrisoquine.
Ambrisentan	Debrisoquine may increase the hypotensive activities of Ambrisentan.
Amifostine	Debrisoquine may increase the hypotensive activities of Amifostine.
Amiloride	Amiloride may increase the hypotensive activities of Debrisoquine.
Aminophenazone	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Aminophenazone.
Amiodarone	The metabolism of Debrisoquine can be decreased when combined with Amiodarone.
Amitriptyline	The metabolism of Amitriptyline can be decreased when combined with Debrisoquine.
Amitriptylinoxide	Amitriptylinoxide may decrease the antihypertensive activities of Debrisoquine.
Amlodipine	Amlodipine may increase the hypotensive activities of Debrisoquine.
Amoxapine	The metabolism of Amoxapine can be decreased when combined with Debrisoquine.
Amphetamine	Amphetamine may decrease the antihypertensive activities of Debrisoquine.
Amphotericin B	Amphotericin B may increase the hypotensive activities of Debrisoquine.
Amprenavir	The metabolism of Debrisoquine can be decreased when combined with Amprenavir.
Amyl Nitrite	Amyl Nitrite may increase the hypotensive activities of Debrisoquine.
Anakinra	The metabolism of Debrisoquine can be increased when combined with Anakinra.
Antipyrine	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Antipyrine.
Antrafenine	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Antrafenine.
Apomorphine	Apomorphine may increase the hypotensive activities of Debrisoquine.
Apremilast	The metabolism of Debrisoquine can be increased when combined with Apremilast.
Aprocitentan	Debrisoquine may increase the hypotensive activities of Aprocitentan.
Arbutamine	Arbutamine may decrease the antihypertensive activities of Debrisoquine.
Arformoterol	Arformoterol may decrease the antihypertensive activities of Debrisoquine.
Aripiprazole	The risk or severity of hypotension can be increased when Aripiprazole is combined with Debrisoquine.
Aripiprazole lauroxil	The risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Debrisoquine.
Arsenic trioxide	Arsenic trioxide may increase the hypotensive activities of Debrisoquine.
Artenimol	The metabolism of Debrisoquine can be decreased when combined with Artenimol.
Asenapine	Asenapine may decrease the antihypertensive activities of Debrisoquine.
Astemizole	The metabolism of Astemizole can be decreased when combined with Debrisoquine.
Asunaprevir	The metabolism of Debrisoquine can be decreased when combined with Asunaprevir.
Atenolol	Atenolol may increase the hypotensive activities of Debrisoquine.
Atomoxetine	Atomoxetine may decrease the antihypertensive activities of Debrisoquine.
Atropine	Atropine may decrease the antihypertensive activities of Debrisoquine.
Avanafil	Debrisoquine may increase the hypotensive activities of Avanafil.
Azelastine	The metabolism of Debrisoquine can be decreased when combined with Azelastine.
Azilsartan medoxomil	Debrisoquine may increase the hypotensive activities of Azilsartan medoxomil.
Baclofen	The risk or severity of adverse effects can be increased when Baclofen is combined with Debrisoquine.
Balsalazide	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Balsalazide.
Benazepril	Benazepril may increase the hypotensive activities of Debrisoquine.
Bendroflumethiazide	The therapeutic efficacy of Debrisoquine can be increased when used in combination with Bendroflumethiazide.
Benorilate	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Benorilate.
Benoxaprofen	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Benoxaprofen.
Benzatropine	The metabolism of Debrisoquine can be decreased when combined with Benzatropine.
Benzocaine	The metabolism of Debrisoquine can be decreased when combined with Benzocaine.
Benzphetamine	Benzphetamine may decrease the antihypertensive activities of Debrisoquine.
Benzthiazide	The therapeutic efficacy of Debrisoquine can be increased when used in combination with Benzthiazide.
Benzydamine	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Benzydamine.
Benzyl alcohol	The metabolism of Benzyl alcohol can be decreased when combined with Debrisoquine.
Bepridil	The metabolism of Debrisoquine can be decreased when combined with Bepridil.
Berotralstat	The metabolism of Debrisoquine can be decreased when combined with Berotralstat.
Betaxolol	Betaxolol may increase the hypotensive activities of Debrisoquine.
Bethanidine	Bethanidine may decrease the antihypertensive activities of Debrisoquine.
Bimatoprost	Bimatoprost may increase the hypotensive activities of Debrisoquine.
Bimekizumab	The metabolism of Debrisoquine can be increased when combined with Bimekizumab.
Biperiden	The metabolism of Debrisoquine can be decreased when combined with Biperiden.
Bisoprolol	Bisoprolol may increase the hypotensive activities of Debrisoquine.
Bortezomib	The metabolism of Debrisoquine can be decreased when combined with Bortezomib.
Bosentan	Bosentan may increase the hypotensive activities of Debrisoquine.
Bretylium	Bretylium may increase the hypotensive activities of Debrisoquine.
Brexpiprazole	Brexpiprazole may decrease the antihypertensive activities of Debrisoquine.
Brimonidine	Brimonidine may increase the antihypertensive activities of Debrisoquine.
Bromocriptine	Bromocriptine may decrease the antihypertensive activities of Debrisoquine.
Bumadizone	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Bumadizone.
Bumetanide	Bumetanide may increase the hypotensive activities of Debrisoquine.
Bupivacaine	The metabolism of Debrisoquine can be decreased when combined with Bupivacaine.
Buprenorphine	The metabolism of Debrisoquine can be decreased when combined with Buprenorphine.
Bupropion	The metabolism of Debrisoquine can be decreased when combined with Bupropion.
Buspirone	Buspirone may decrease the antihypertensive activities of Debrisoquine.
Butriptyline	Butriptyline may decrease the antihypertensive activities of Debrisoquine.
Cabergoline	Cabergoline may decrease the antihypertensive activities of Debrisoquine.
Canagliflozin	Canagliflozin may increase the hypotensive activities of Debrisoquine.
Canakinumab	The metabolism of Debrisoquine can be increased when combined with Canakinumab.
Candesartan cilexetil	Candesartan cilexetil may increase the hypotensive activities of Debrisoquine.
Cannabidiol	The metabolism of Debrisoquine can be decreased when combined with Cannabidiol.
Captopril	Captopril may increase the hypotensive activities of Debrisoquine.
Carbetocin	Carbetocin may increase the hypotensive activities of Debrisoquine.
Carbidopa	The risk or severity of hypotension can be increased when Carbidopa is combined with Debrisoquine.
Cariprazine	Cariprazine may decrease the antihypertensive activities of Debrisoquine.
Carprofen	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Carprofen.
Carteolol	Carteolol may increase the hypotensive activities of Debrisoquine.
Carvedilol	Carvedilol may increase the hypotensive activities of Debrisoquine.
Celecoxib	The metabolism of Debrisoquine can be decreased when combined with Celecoxib.
Celiprolol	Debrisoquine may increase the hypotensive activities of Celiprolol.
Cerivastatin	The metabolism of Debrisoquine can be decreased when combined with Cerivastatin.
Certolizumab pegol	The metabolism of Debrisoquine can be increased when combined with Certolizumab pegol.
Cevimeline	The metabolism of Debrisoquine can be decreased when combined with Cevimeline.
Chloroquine	The metabolism of Debrisoquine can be decreased when combined with Chloroquine.
Chlorothiazide	The therapeutic efficacy of Debrisoquine can be increased when used in combination with Chlorothiazide.
Chlorpheniramine	The metabolism of Debrisoquine can be decreased when combined with Chlorpheniramine.
Chlorpromazine	The metabolism of Debrisoquine can be decreased when combined with Chlorpromazine.
Chlorthalidone	Chlorthalidone may increase the hypotensive activities of Debrisoquine.
Chlorzoxazone	The metabolism of Debrisoquine can be decreased when combined with Chlorzoxazone.
Cholecalciferol	The metabolism of Debrisoquine can be decreased when combined with Cholecalciferol.
Choline magnesium trisalicylate	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Choline magnesium trisalicylate.
Ciclesonide	The metabolism of Debrisoquine can be decreased when combined with Ciclesonide.
Cilazapril	Cilazapril may increase the hypotensive activities of Debrisoquine.
Cilostazol	The metabolism of Debrisoquine can be decreased when combined with Cilostazol.
Cimetidine	The metabolism of Debrisoquine can be decreased when combined with Cimetidine.
Cinacalcet	The metabolism of Debrisoquine can be decreased when combined with Cinacalcet.
Cinnarizine	The metabolism of Debrisoquine can be decreased when combined with Cinnarizine.
Cisapride	The metabolism of Debrisoquine can be decreased when combined with Cisapride.
Citalopram	The metabolism of Debrisoquine can be decreased when combined with Citalopram.
Clemastine	The metabolism of Debrisoquine can be decreased when combined with Clemastine.
Clenbuterol	Clenbuterol may decrease the antihypertensive activities of Debrisoquine.
Clevidipine	The metabolism of Clevidipine can be decreased when combined with Debrisoquine.
Clobazam	The serum concentration of Debrisoquine can be increased when it is combined with Clobazam.
Clofarabine	Clofarabine may increase the hypotensive activities of Debrisoquine.
Clomipramine	The metabolism of Clomipramine can be decreased when combined with Debrisoquine.
Clonidine	The risk or severity of hypotension can be increased when Clonidine is combined with Debrisoquine.
Clozapine	The serum concentration of Debrisoquine can be increased when it is combined with Clozapine.
Cobicistat	The metabolism of Debrisoquine can be decreased when combined with Cobicistat.
Cocaine	The metabolism of Debrisoquine can be decreased when combined with Cocaine.
Codeine	The metabolism of Debrisoquine can be decreased when combined with Codeine.
Conivaptan	Conivaptan may increase the hypotensive activities of Debrisoquine.
Cryptenamine	Cryptenamine may increase the hypotensive activities of Debrisoquine.
Curcumin	The metabolism of Debrisoquine can be decreased when combined with Curcumin.
Cyclopenthiazide	The therapeutic efficacy of Debrisoquine can be increased when used in combination with Cyclopenthiazide.
Cyclosporine	The metabolism of Debrisoquine can be decreased when combined with Cyclosporine.
Cyclothiazide	The therapeutic efficacy of Debrisoquine can be increased when used in combination with Cyclothiazide.
Dacomitinib	The metabolism of Dacomitinib can be decreased when combined with Debrisoquine.
Dapagliflozin	Dapagliflozin may increase the hypotensive activities of Debrisoquine.
Darifenacin	The metabolism of Debrisoquine can be decreased when combined with Darifenacin.
Darunavir	The metabolism of Debrisoquine can be decreased when combined with Darunavir.
Dasabuvir	The metabolism of Dasabuvir can be decreased when combined with Debrisoquine.
Dasiglucagon	Debrisoquine may increase the hypotensive activities of Dasiglucagon.
Delavirdine	The metabolism of Debrisoquine can be decreased when combined with Delavirdine.
Deserpidine	Deserpidine may increase the hypotensive activities of Debrisoquine.
Desflurane	Desflurane may decrease the antihypertensive activities of Debrisoquine.
Desipramine	The metabolism of Debrisoquine can be decreased when combined with Desipramine.
Desmopressin	Desmopressin may decrease the antihypertensive activities of Debrisoquine.
Desvenlafaxine	The serum concentration of Debrisoquine can be increased when it is combined with Desvenlafaxine.
Deutetrabenazine	The metabolism of Deutetrabenazine can be decreased when combined with Debrisoquine.
Dexchlorpheniramine maleate	The metabolism of Debrisoquine can be decreased when combined with Dexchlorpheniramine maleate.
Dexfenfluramine	The metabolism of Debrisoquine can be decreased when combined with Dexfenfluramine.
Dexibuprofen	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Dexibuprofen.
Dexketoprofen	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Dexketoprofen.
Dexmedetomidine	The metabolism of Debrisoquine can be decreased when combined with Dexmedetomidine.
Dexmethylphenidate	Dexmethylphenidate may decrease the antihypertensive activities of Debrisoquine.
Dextroamphetamine	Dextroamphetamine may decrease the antihypertensive activities of Debrisoquine.
Dextromethorphan	The metabolism of Debrisoquine can be decreased when combined with Dextromethorphan.
Dextropropoxyphene	The metabolism of Debrisoquine can be decreased when combined with Dextropropoxyphene.
Diacerein	The metabolism of Debrisoquine can be decreased when combined with Diacerein.
Diazoxide	Diazoxide may increase the hypotensive activities of Debrisoquine.
Dibenzepin	Dibenzepin may decrease the antihypertensive activities of Debrisoquine.
Diclofenac	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Diclofenac.
Diclofenamide	Diclofenamide may increase the hypotensive activities of Debrisoquine.
Diethylpropion	Diethylpropion may decrease the antihypertensive activities of Debrisoquine.
Diflunisal	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Diflunisal.
Dihydralazine	Debrisoquine may increase the hypotensive activities of Dihydralazine.
Dihydrocodeine	The metabolism of Debrisoquine can be decreased when combined with Dihydrocodeine.
Dihydroergocornine	Dihydroergocornine may decrease the antihypertensive activities of Debrisoquine.
Dihydroergocristine	Dihydroergocristine may decrease the antihypertensive activities of Debrisoquine.
Dihydroergotamine	Dihydroergotamine may decrease the antihypertensive activities of Debrisoquine.
Diltiazem	Diltiazem may increase the hypotensive activities of Debrisoquine.
Dimethyl sulfoxide	The metabolism of Debrisoquine can be decreased when combined with Dimethyl sulfoxide.
Dinutuximab	Dinutuximab may increase the hypotensive activities of Debrisoquine.
Diphenhydramine	The metabolism of Debrisoquine can be decreased when combined with Diphenhydramine.
Dipyridamole	Dipyridamole may increase the antihypertensive activities of Debrisoquine.
DL-Methylephedrine	DL-Methylephedrine may decrease the antihypertensive activities of Debrisoquine.
Dobutamine	Dobutamine may decrease the antihypertensive activities of Debrisoquine.
Dolasetron	The metabolism of Debrisoquine can be decreased when combined with Dolasetron.
Domperidone	The metabolism of Debrisoquine can be decreased when combined with Domperidone.
Donepezil	The metabolism of Debrisoquine can be decreased when combined with Donepezil.
Dopamine	Dopamine may decrease the antihypertensive activities of Debrisoquine.
Dopexamine	Dopexamine may decrease the antihypertensive activities of Debrisoquine.
Dorzolamide	Dorzolamide may increase the hypotensive activities of Debrisoquine.
Dosulepin	The metabolism of Debrisoquine can be decreased when combined with Dosulepin.
Doxapram	Doxapram may decrease the antihypertensive activities of Debrisoquine.
Doxazosin	Doxazosin may increase the hypotensive activities of Debrisoquine.
Doxepin	Doxepin may decrease the antihypertensive activities of Debrisoquine.
Doxorubicin	The metabolism of Debrisoquine can be decreased when combined with Doxorubicin.
Dronabinol	The metabolism of Debrisoquine can be decreased when combined with Dronabinol.
Dronedarone	The metabolism of Debrisoquine can be decreased when combined with Dronedarone.
Droperidol	Droperidol may decrease the antihypertensive activities of Debrisoquine.
Droxidopa	Droxidopa may decrease the antihypertensive activities of Debrisoquine.
Duloxetine	The metabolism of Debrisoquine can be decreased when combined with Duloxetine.
Dutasteride	Dutasteride may decrease the antihypertensive activities of Debrisoquine.
Elagolix	The metabolism of Elagolix can be decreased when combined with Debrisoquine.
Eletriptan	Eletriptan may decrease the antihypertensive activities of Debrisoquine.
Eliglustat	The metabolism of Debrisoquine can be decreased when combined with Eliglustat.
Emapalumab	The metabolism of Debrisoquine can be increased when combined with Emapalumab.
Empagliflozin	Empagliflozin may increase the hypotensive activities of Debrisoquine.
Enalapril	Enalapril may increase the hypotensive activities of Debrisoquine.
Enalaprilat	Debrisoquine may increase the hypotensive activities of Enalaprilat.
Enasidenib	The metabolism of Enasidenib can be decreased when combined with Debrisoquine.
Encainide	The metabolism of Debrisoquine can be decreased when combined with Encainide.
Encorafenib	The metabolism of Debrisoquine can be decreased when combined with Encorafenib.
Entacapone	The metabolism of Debrisoquine can be decreased when combined with Entacapone.
Ephedrine	Ephedrine may decrease the antihypertensive activities of Debrisoquine.
Epinastine	The metabolism of Debrisoquine can be decreased when combined with Epinastine.
Epinephrine	Epinephrine may decrease the antihypertensive activities of Debrisoquine.
Eplerenone	Eplerenone may increase the hypotensive activities of Debrisoquine.
Epoprostenol	Epoprostenol may increase the hypotensive activities of Debrisoquine.
Eprosartan	Eprosartan may increase the hypotensive activities of Debrisoquine.
Ergoloid mesylate	Ergoloid mesylate may decrease the antihypertensive activities of Debrisoquine.
Ergometrine	Ergometrine may decrease the antihypertensive activities of Debrisoquine.
Ergotamine	Ergotamine may decrease the antihypertensive activities of Debrisoquine.
Erlotinib	The metabolism of Erlotinib can be decreased when combined with Debrisoquine.
Escitalopram	The serum concentration of Debrisoquine can be increased when it is combined with Escitalopram.
Esmolol	Esmolol may increase the hypotensive activities of Debrisoquine.
Etacrynic acid	Etacrynic acid may increase the hypotensive activities of Debrisoquine.
Etafedrine	Etafedrine may decrease the antihypertensive activities of Debrisoquine.
Etanercept	The metabolism of Debrisoquine can be increased when combined with Etanercept.
Ethambutol	The metabolism of Debrisoquine can be decreased when combined with Ethambutol.
Etilefrine	Etilefrine may decrease the antihypertensive activities of Debrisoquine.
Etodolac	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Etodolac.
Etomidate	Etomidate may decrease the antihypertensive activities of Debrisoquine.
Etoricoxib	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Etoricoxib.
Everolimus	The metabolism of Debrisoquine can be decreased when combined with Everolimus.
Fedratinib	The serum concentration of Debrisoquine can be increased when it is combined with Fedratinib.
Felodipine	The metabolism of Debrisoquine can be decreased when combined with Felodipine.
Fenbufen	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Fenbufen.
Fenfluramine	The metabolism of Debrisoquine can be decreased when combined with Fenfluramine.
Fenoldopam	Fenoldopam may increase the hypotensive activities of Debrisoquine.
Fenoprofen	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Fenoprofen.
Fenoterol	Fenoterol may decrease the antihypertensive activities of Debrisoquine.
Fentanyl	Fentanyl may decrease the antihypertensive activities of Debrisoquine.
Fesoterodine	The metabolism of Fesoterodine can be decreased when combined with Debrisoquine.
Fexinidazole	The metabolism of Fexinidazole can be decreased when combined with Debrisoquine.
Finasteride	Finasteride may decrease the antihypertensive activities of Debrisoquine.
Flecainide	The metabolism of Flecainide can be decreased when combined with Debrisoquine.
Flibanserin	Flibanserin may decrease the antihypertensive activities of Debrisoquine.
Floctafenine	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Floctafenine.
Flunarizine	The metabolism of Flunarizine can be decreased when combined with Debrisoquine.
Fluoxetine	The serum concentration of Debrisoquine can be increased when it is combined with Fluoxetine.
Flupentixol	Flupentixol may decrease the antihypertensive activities of Debrisoquine.
Fluphenazine	The metabolism of Debrisoquine can be decreased when combined with Fluphenazine.
Flurbiprofen	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Flurbiprofen.
Fluvastatin	The metabolism of Debrisoquine can be decreased when combined with Fluvastatin.
Fluvoxamine	The metabolism of Debrisoquine can be decreased when combined with Fluvoxamine.
Formoterol	Formoterol may decrease the antihypertensive activities of Debrisoquine.
Fosinopril	Fosinopril may increase the hypotensive activities of Debrisoquine.
Fostamatinib	Fostamatinib may increase the antihypertensive activities of Debrisoquine.
Frovatriptan	Frovatriptan may decrease the antihypertensive activities of Debrisoquine.
Furosemide	Furosemide may increase the hypotensive activities of Debrisoquine.
Fusidic acid	The metabolism of Debrisoquine can be decreased when combined with Fusidic acid.
Galantamine	The metabolism of Debrisoquine can be decreased when combined with Galantamine.
Gefitinib	The metabolism of Debrisoquine can be decreased when combined with Gefitinib.
Givosiran	The serum concentration of Debrisoquine can be increased when it is combined with Givosiran.
Glycerol phenylbutyrate	The metabolism of Debrisoquine can be decreased when combined with Glycerol phenylbutyrate.
Glycol salicylate	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Glycol salicylate.
Golimumab	The metabolism of Debrisoquine can be increased when combined with Golimumab.
Guanabenz	Guanabenz may decrease the antihypertensive activities of Debrisoquine.
Guanadrel	Guanadrel may increase the hypotensive activities of Debrisoquine.
Guanethidine	Guanethidine may increase the hypotensive activities of Debrisoquine.
Guanfacine	Guanfacine may decrease the antihypertensive activities of Debrisoquine.
Guanoxan	Debrisoquine may increase the hypotensive activities of Guanoxan.
Halofantrine	The metabolism of Debrisoquine can be decreased when combined with Halofantrine.
Haloperidol	The serum concentration of Debrisoquine can be increased when it is combined with Haloperidol.
Halothane	Halothane may decrease the antihypertensive activities of Debrisoquine.
Hydralazine	Hydralazine may increase the hypotensive activities of Debrisoquine.
Hydrochlorothiazide	The therapeutic efficacy of Debrisoquine can be increased when used in combination with Hydrochlorothiazide.
Hydroflumethiazide	The therapeutic efficacy of Debrisoquine can be increased when used in combination with Hydroflumethiazide.
Hydroxychloroquine	The metabolism of Debrisoquine can be decreased when combined with Hydroxychloroquine.
Hydroxyzine	The metabolism of Debrisoquine can be decreased when combined with Hydroxyzine.
Ibrutinib	The metabolism of Ibrutinib can be decreased when combined with Debrisoquine.
Ibuprofen	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Ibuprofen.
Icosapent	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Icosapent.
Idarubicin	The metabolism of Debrisoquine can be decreased when combined with Idarubicin.
Iloperidone	Iloperidone may decrease the antihypertensive activities of Debrisoquine.
Iloprost	Iloprost may increase the hypotensive activities of Debrisoquine.
Imatinib	The serum concentration of Debrisoquine can be increased when it is combined with Imatinib.
Imipramine	The metabolism of Debrisoquine can be decreased when combined with Imipramine.
Indacaterol	Indacaterol may decrease the antihypertensive activities of Debrisoquine.
Indapamide	The therapeutic efficacy of Indapamide can be increased when used in combination with Debrisoquine.
Indomethacin	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Indomethacin.
Indoramin	Indoramin may decrease the antihypertensive activities of Debrisoquine.
Infliximab	The metabolism of Debrisoquine can be increased when combined with Infliximab.
Iofetamine I-123	Iofetamine I-123 may decrease the antihypertensive activities of Debrisoquine.
Ipecac	The metabolism of Ipecac can be decreased when combined with Debrisoquine.
Iptacopan	The metabolism of Iptacopan can be decreased when combined with Debrisoquine.
Irbesartan	Irbesartan may increase the hypotensive activities of Debrisoquine.
Isavuconazole	The metabolism of Debrisoquine can be decreased when combined with Isavuconazole.
Isavuconazonium	The metabolism of Debrisoquine can be decreased when combined with Isavuconazonium.
Isocarboxazid	Isocarboxazid may increase the hypotensive activities of Debrisoquine.
Isoetharine	Isoetharine may decrease the antihypertensive activities of Debrisoquine.
Isoflurane	Isoflurane may decrease the antihypertensive activities of Debrisoquine.
Isometheptene	Isometheptene may decrease the antihypertensive activities of Debrisoquine.
Isoprenaline	Isoprenaline may decrease the antihypertensive activities of Debrisoquine.
Isosorbide dinitrate	Isosorbide dinitrate may increase the hypotensive activities of Debrisoquine.
Isosorbide mononitrate	Isosorbide mononitrate may increase the hypotensive activities of Debrisoquine.
Isoxicam	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Isoxicam.
Isoxsuprine	Isoxsuprine may decrease the antihypertensive activities of Debrisoquine.
Isradipine	Isradipine may increase the hypotensive activities of Debrisoquine.
Istradefylline	The metabolism of Istradefylline can be decreased when combined with Debrisoquine.
Ketoconazole	The metabolism of Debrisoquine can be decreased when combined with Ketoconazole.
Ketoprofen	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Ketoprofen.
Ketorolac	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Ketorolac.
Labetalol	The metabolism of Debrisoquine can be decreased when combined with Labetalol.
Lacidipine	Debrisoquine may increase the hypotensive activities of Lacidipine.
Lansoprazole	The metabolism of Debrisoquine can be decreased when combined with Lansoprazole.
Lercanidipine	Lercanidipine may increase the hypotensive activities of Debrisoquine.
Levamlodipine	Debrisoquine may increase the hypotensive activities of Levamlodipine.
Levobetaxolol	The metabolism of Levobetaxolol can be decreased when combined with Debrisoquine.
Levobupivacaine	Levobupivacaine may increase the hypotensive activities of Debrisoquine.
Levodopa	Levodopa may increase the hypotensive activities of Debrisoquine.
Levonordefrin	Levonordefrin may decrease the antihypertensive activities of Debrisoquine.
Levosalbutamol	Levosalbutamol may decrease the antihypertensive activities of Debrisoquine.
Levosimendan	Levosimendan may increase the hypotensive activities of Debrisoquine.
Lidocaine	The metabolism of Debrisoquine can be decreased when combined with Lidocaine.
Linezolid	Linezolid may increase the hypotensive activities of Debrisoquine.
Lisdexamfetamine	Lisdexamfetamine may decrease the antihypertensive activities of Debrisoquine.
Lisinopril	Lisinopril may increase the hypotensive activities of Debrisoquine.
Lisuride	Lisuride may decrease the antihypertensive activities of Debrisoquine.
Lofexidine	Lofexidine may decrease the antihypertensive activities of Debrisoquine.
Lorcaserin	The metabolism of Debrisoquine can be decreased when combined with Lorcaserin.
Lornoxicam	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Lornoxicam.
Lorpiprazole	The metabolism of Lorpiprazole can be decreased when combined with Debrisoquine.
Losartan	Losartan may increase the hypotensive activities of Debrisoquine.
Loxoprofen	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Loxoprofen.
Lumefantrine	The metabolism of Debrisoquine can be decreased when combined with Lumefantrine.
Lumiracoxib	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Lumiracoxib.
Lurasidone	Lurasidone may decrease the antihypertensive activities of Debrisoquine.
Macitentan	Debrisoquine may increase the hypotensive activities of Macitentan.
Manidipine	The metabolism of Debrisoquine can be decreased when combined with Manidipine.
Mannitol	Mannitol may increase the hypotensive activities of Debrisoquine.
Maprotiline	The metabolism of Debrisoquine can be decreased when combined with Maprotiline.
Mazindol	The risk or severity of adverse effects can be increased when Mazindol is combined with Debrisoquine.
Mecamylamine	Mecamylamine may increase the hypotensive activities of Debrisoquine.
Meclizine	The metabolism of Debrisoquine can be decreased when combined with Meclizine.
Meclofenamic acid	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Meclofenamic acid.
Mefenamic acid	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Mefenamic acid.
Meloxicam	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Meloxicam.
Menthyl salicylate	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Menthyl salicylate.
Mephentermine	Mephentermine may decrease the antihypertensive activities of Debrisoquine.
Mephenytoin	The metabolism of Debrisoquine can be decreased when combined with Mephenytoin.
Mepyramine	The metabolism of Debrisoquine can be decreased when combined with Mepyramine.
Mesalazine	Mesalazine may decrease the antihypertensive activities of Debrisoquine.
Mesoridazine	The metabolism of Debrisoquine can be decreased when combined with Mesoridazine.
Metamfetamine	Metamfetamine may decrease the antihypertensive activities of Debrisoquine.
Metamizole	Metamizole may decrease the antihypertensive activities of Debrisoquine.
Metaraminol	Metaraminol may decrease the antihypertensive activities of Debrisoquine.
Metergoline	Metergoline may decrease the antihypertensive activities of Debrisoquine.
Methadone	The metabolism of Debrisoquine can be decreased when combined with Methadone.
Methazolamide	Methazolamide may increase the hypotensive activities of Debrisoquine.
Methimazole	The metabolism of Debrisoquine can be decreased when combined with Methimazole.
Methotrimeprazine	The metabolism of Debrisoquine can be decreased when combined with Methotrimeprazine.
Methoxamine	Methoxamine may decrease the antihypertensive activities of Debrisoquine.
Methoxyflurane	Methoxyflurane may decrease the antihypertensive activities of Debrisoquine.
Methoxyphenamine	Methoxyphenamine may decrease the antihypertensive activities of Debrisoquine.
Methyldopa	Methyldopa may increase the hypotensive activities of Debrisoquine.
Methylene blue	Methylene blue may increase the hypotensive activities of Debrisoquine.
Methylergometrine	Methylergometrine may decrease the antihypertensive activities of Debrisoquine.
Methylphenidate	Methylphenidate may decrease the antihypertensive activities of Debrisoquine.
Methysergide	Methysergide may decrease the antihypertensive activities of Debrisoquine.
Metipranolol	Metipranolol may increase the hypotensive activities of Debrisoquine.
Metoclopramide	The metabolism of Debrisoquine can be decreased when combined with Metoclopramide.
Metolazone	Metolazone may increase the hypotensive activities of Debrisoquine.
Metoprolol	The metabolism of Debrisoquine can be decreased when combined with Metoprolol.
Metyrosine	Metyrosine may increase the hypotensive activities of Debrisoquine.
Mexiletine	The metabolism of Debrisoquine can be decreased when combined with Mexiletine.
Mianserin	Mianserin may decrease the antihypertensive activities of Debrisoquine.
Miconazole	The metabolism of Debrisoquine can be decreased when combined with Miconazole.
Midodrine	Midodrine may decrease the antihypertensive activities of Debrisoquine.
Mifepristone	The metabolism of Debrisoquine can be decreased when combined with Mifepristone.
Minaprine	Minaprine may increase the hypotensive activities of Debrisoquine.
Minoxidil	Minoxidil may increase the hypotensive activities of Debrisoquine.
Mirabegron	The serum concentration of Debrisoquine can be increased when it is combined with Mirabegron.
Mirtazapine	Mirtazapine may decrease the antihypertensive activities of Debrisoquine.
Moclobemide	Moclobemide may increase the hypotensive activities of Debrisoquine.
Moexipril	Moexipril may increase the hypotensive activities of Debrisoquine.
Molsidomine	Molsidomine may increase the hypotensive activities of Debrisoquine.
Morphine	Morphine may increase the hypotensive activities of Debrisoquine.
Moxisylyte	Moxisylyte may decrease the antihypertensive activities of Debrisoquine.
Moxonidine	Moxonidine may decrease the antihypertensive activities of Debrisoquine.
Muzolimine	Debrisoquine may increase the hypotensive activities of Muzolimine.
Nabilone	Nabilone may increase the hypotensive activities of Debrisoquine.
Nabumetone	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Nabumetone.
Nadolol	Nadolol may increase the hypotensive activities of Debrisoquine.
Naphazoline	Naphazoline may decrease the antihypertensive activities of Debrisoquine.
Naproxen	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Naproxen.
Naratriptan	Naratriptan may decrease the antihypertensive activities of Debrisoquine.
Nateglinide	The metabolism of Debrisoquine can be decreased when combined with Nateglinide.
Naxitamab	Naxitamab may decrease the antihypertensive activities of Debrisoquine.
Nebivolol	Debrisoquine may increase the hypotensive activities of Nebivolol.
Nefazodone	Nefazodone may decrease the antihypertensive activities of Debrisoquine.
Nesiritide	Nesiritide may increase the hypotensive activities of Debrisoquine.
Netupitant	The metabolism of Netupitant can be decreased when combined with Debrisoquine.
Nevirapine	The metabolism of Debrisoquine can be decreased when combined with Nevirapine.
Niacin	The metabolism of Debrisoquine can be decreased when combined with Niacin.
Nialamide	Nialamide may increase the hypotensive activities of Debrisoquine.
Nicardipine	The metabolism of Debrisoquine can be decreased when combined with Nicardipine.
Nicergoline	Nicergoline may decrease the antihypertensive activities of Debrisoquine.
Nicorandil	Debrisoquine may increase the hypotensive activities of Nicorandil.
Nifedipine	The metabolism of Debrisoquine can be decreased when combined with Nifedipine.
Nilvadipine	Debrisoquine may increase the hypotensive activities of Nilvadipine.
Nimesulide	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Nimesulide.
Nimodipine	Nimodipine may increase the hypotensive activities of Debrisoquine.
Nirogacestat	The metabolism of Nirogacestat can be decreased when combined with Debrisoquine.
Nisoldipine	Nisoldipine may increase the hypotensive activities of Debrisoquine.
Nitrendipine	Nitrendipine may increase the hypotensive activities of Debrisoquine.
Nitric Oxide	Nitric Oxide may increase the hypotensive activities of Debrisoquine.
Nitroglycerin	Nitroglycerin may increase the hypotensive activities of Debrisoquine.
Nitroprusside	Nitroprusside may increase the hypotensive activities of Debrisoquine.
Nitrous acid	Nitrous acid may increase the hypotensive activities of Debrisoquine.
Nitrous oxide	Nitrous oxide may decrease the antihypertensive activities of Debrisoquine.
Norepinephrine	Norepinephrine may decrease the antihypertensive activities of Debrisoquine.
Nortriptyline	The metabolism of Nortriptyline can be decreased when combined with Debrisoquine.
Nylidrin	Nylidrin may decrease the antihypertensive activities of Debrisoquine.
Obinutuzumab	Debrisoquine may increase the hypotensive activities of Obinutuzumab.
Olanzapine	The metabolism of Debrisoquine can be decreased when combined with Olanzapine.
Oliceridine	The metabolism of Oliceridine can be decreased when combined with Debrisoquine.
Olmesartan	Olmesartan may increase the hypotensive activities of Debrisoquine.
Olodaterol	Olodaterol may decrease the antihypertensive activities of Debrisoquine.
Ondansetron	The metabolism of Debrisoquine can be decreased when combined with Ondansetron.
Opicapone	Opicapone may increase the hypotensive activities of Debrisoquine.
Opium	The metabolism of Opium can be decreased when combined with Debrisoquine.
Orciprenaline	Orciprenaline may decrease the antihypertensive activities of Debrisoquine.
Oritavancin	The metabolism of Debrisoquine can be decreased when combined with Oritavancin.
Orphenadrine	The metabolism of Debrisoquine can be decreased when combined with Orphenadrine.
Osilodrostat	The metabolism of Debrisoquine can be decreased when combined with Osilodrostat.
Ospemifene	The metabolism of Debrisoquine can be decreased when combined with Ospemifene.
Oxamniquine	The metabolism of Debrisoquine can be decreased when combined with Oxamniquine.
Oxaprozin	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Oxaprozin.
Oxprenolol	The metabolism of Debrisoquine can be decreased when combined with Oxprenolol.
Oxybutynin	The metabolism of Debrisoquine can be decreased when combined with Oxybutynin.
Oxycodone	The metabolism of Debrisoquine can be decreased when combined with Oxycodone.
Oxymetazoline	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Oxymetazoline.
Oxymorphone	The metabolism of Debrisoquine can be decreased when combined with Oxymorphone.
Oxyphenbutazone	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Oxyphenbutazone.
Paclitaxel	Paclitaxel may increase the hypotensive activities of Debrisoquine.
Paliperidone	Paliperidone may decrease the antihypertensive activities of Debrisoquine.
Palonosetron	The metabolism of Debrisoquine can be decreased when combined with Palonosetron.
Panobinostat	The metabolism of Debrisoquine can be decreased when combined with Panobinostat.
Papaverine	Papaverine may increase the hypotensive activities of Debrisoquine.
Parecoxib	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Parecoxib.
Pargyline	Pargyline may increase the hypotensive activities of Debrisoquine.
Paroxetine	The metabolism of Debrisoquine can be decreased when combined with Paroxetine.
Pazopanib	The metabolism of Debrisoquine can be decreased when combined with Pazopanib.
Peginterferon alfa-2b	The metabolism of Debrisoquine can be decreased when combined with Peginterferon alfa-2b.
Penbutolol	Penbutolol may increase the hypotensive activities of Debrisoquine.
Pentamidine	The metabolism of Debrisoquine can be decreased when combined with Pentamidine.
Pentolinium	Pentolinium may increase the hypotensive activities of Debrisoquine.
Pentoxifylline	Pentoxifylline may increase the hypotensive activities of Debrisoquine.
Pergolide	Pergolide may decrease the antihypertensive activities of Debrisoquine.
Perhexiline	The metabolism of Debrisoquine can be decreased when combined with Perhexiline.
Periciazine	Periciazine may decrease the antihypertensive activities of Debrisoquine.
Perindopril	Perindopril may increase the hypotensive activities of Debrisoquine.
Perphenazine	The metabolism of Debrisoquine can be decreased when combined with Perphenazine.
Phendimetrazine	Phendimetrazine may decrease the antihypertensive activities of Debrisoquine.
Phenelzine	Phenelzine may increase the hypotensive activities of Debrisoquine.
Phenformin	The metabolism of Debrisoquine can be decreased when combined with Phenformin.
Phenmetrazine	Phenmetrazine may decrease the antihypertensive activities of Debrisoquine.
Phenoxybenzamine	Phenoxybenzamine may decrease the antihypertensive activities of Debrisoquine.
Phentermine	Phentermine may decrease the antihypertensive activities of Debrisoquine.
Phentolamine	Phentolamine may decrease the antihypertensive activities of Debrisoquine.
Phenylbutazone	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Phenylbutazone.
Phenylbutyric acid	The metabolism of Debrisoquine can be decreased when combined with Phenylbutyric acid.
Phenylephrine	Phenylephrine may decrease the antihypertensive activities of Debrisoquine.
Phenylpropanolamine	Phenylpropanolamine may decrease the antihypertensive activities of Debrisoquine.
Phenytoin	The metabolism of Debrisoquine can be decreased when combined with Phenytoin.
Pimozide	The metabolism of Pimozide can be decreased when combined with Debrisoquine.
Pinacidil	Debrisoquine may increase the hypotensive activities of Pinacidil.
Pindolol	Pindolol may increase the hypotensive activities of Debrisoquine.
Piperazine	The metabolism of Debrisoquine can be decreased when combined with Piperazine.
Pipotiazine	The metabolism of Debrisoquine can be decreased when combined with Pipotiazine.
Pirbuterol	Pirbuterol may decrease the antihypertensive activities of Debrisoquine.
Pirfenidone	The metabolism of Pirfenidone can be decreased when combined with Debrisoquine.
Piroxicam	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Piroxicam.
Pitolisant	The metabolism of Debrisoquine can be decreased when combined with Pitolisant.
Pizotifen	Pizotifen may decrease the antihypertensive activities of Debrisoquine.
Polythiazide	The therapeutic efficacy of Debrisoquine can be increased when used in combination with Polythiazide.
Ponatinib	The metabolism of Ponatinib can be decreased when combined with Debrisoquine.
Practolol	Practolol may increase the hypotensive activities of Debrisoquine.
Pramipexole	Pramipexole may increase the hypotensive activities of Debrisoquine.
Prazosin	The risk or severity of hypotension can be increased when Prazosin is combined with Debrisoquine.
Primaquine	The metabolism of Debrisoquine can be decreased when combined with Primaquine.
Procainamide	The metabolism of Procainamide can be decreased when combined with Debrisoquine.
Procaine	Procaine may increase the hypotensive activities of Debrisoquine.
Procarbazine	Procarbazine may increase the hypotensive activities of Debrisoquine.
Procaterol	Procaterol may decrease the antihypertensive activities of Debrisoquine.
Prochlorperazine	The metabolism of Debrisoquine can be decreased when combined with Prochlorperazine.
Progesterone	The metabolism of Debrisoquine can be decreased when combined with Progesterone.
Proguanil	The metabolism of Debrisoquine can be decreased when combined with Proguanil.
Promazine	Promazine may decrease the antihypertensive activities of Debrisoquine.
Promethazine	The metabolism of Debrisoquine can be decreased when combined with Promethazine.
Propafenone	The metabolism of Debrisoquine can be decreased when combined with Propafenone.
Propiomazine	Propiomazine may decrease the antihypertensive activities of Debrisoquine.
Propiverine	Propiverine may decrease the antihypertensive activities of Debrisoquine.
Propofol	Propofol may decrease the antihypertensive activities of Debrisoquine.
Propranolol	Propranolol may increase the hypotensive activities of Debrisoquine.
Protriptyline	Protriptyline may decrease the antihypertensive activities of Debrisoquine.
Pseudoephedrine	Pseudoephedrine may decrease the antihypertensive activities of Debrisoquine.
Quetiapine	Quetiapine may increase the hypotensive activities of Debrisoquine.
Quinapril	Quinapril may increase the hypotensive activities of Debrisoquine.
Quinidine	The metabolism of Debrisoquine can be decreased when combined with Quinidine.
Quinine	The metabolism of Debrisoquine can be decreased when combined with Quinine.
Quinupramine	Quinupramine may decrease the antihypertensive activities of Debrisoquine.
Racepinephrine	Racepinephrine may decrease the antihypertensive activities of Debrisoquine.
Ramipril	Ramipril may increase the hypotensive activities of Debrisoquine.
Ranitidine	The metabolism of Debrisoquine can be decreased when combined with Ranitidine.
Ranolazine	The serum concentration of Debrisoquine can be increased when it is combined with Ranolazine.
Rasagiline	Rasagiline may increase the hypotensive activities of Debrisoquine.
Reboxetine	The metabolism of Debrisoquine can be decreased when combined with Reboxetine.
Remifentanil	Remifentanil may decrease the antihypertensive activities of Debrisoquine.
Remoxipride	The metabolism of Debrisoquine can be decreased when combined with Remoxipride.
Rescinnamine	Rescinnamine may decrease the antihypertensive activities of Debrisoquine.
Reserpine	Reserpine may increase the hypotensive activities of Debrisoquine.
Revefenacin	The metabolism of Revefenacin can be decreased when combined with Debrisoquine.
Rilmenidine	Rilmenidine may decrease the antihypertensive activities of Debrisoquine.
Rilonacept	The metabolism of Debrisoquine can be increased when combined with Rilonacept.
Rilpivirine	The metabolism of Debrisoquine can be decreased when combined with Rilpivirine.
Riociguat	Debrisoquine may increase the hypotensive activities of Riociguat.
Risperidone	Risperidone may decrease the antihypertensive activities of Debrisoquine.
Ritodrine	Ritodrine may decrease the antihypertensive activities of Debrisoquine.
Ritonavir	The metabolism of Debrisoquine can be decreased when combined with Ritonavir.
Rituximab	Debrisoquine may increase the hypotensive activities of Rituximab.
Rizatriptan	Rizatriptan may decrease the antihypertensive activities of Debrisoquine.
Rofecoxib	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Rofecoxib.
Rolapitant	The metabolism of Debrisoquine can be decreased when combined with Rolapitant.
Ropeginterferon alfa-2b	The metabolism of Debrisoquine can be decreased when combined with Ropeginterferon alfa-2b.
Ropinirole	Ropinirole may increase the hypotensive activities of Debrisoquine.
Ropivacaine	Ropivacaine may increase the hypotensive activities of Debrisoquine.
Rotigotine	The metabolism of Debrisoquine can be decreased when combined with Rotigotine.
Rucaparib	The metabolism of Debrisoquine can be decreased when combined with Rucaparib.
Rupatadine	The metabolism of Rupatadine can be decreased when combined with Debrisoquine.
Sacubitril	Sacubitril may increase the hypotensive activities of Debrisoquine.
Safinamide	Safinamide may increase the hypotensive activities of Debrisoquine.
Salicylamide	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Salicylamide.
Salicylic acid	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Salicylic acid.
Salmeterol	Salmeterol may decrease the antihypertensive activities of Debrisoquine.
Salsalate	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Salsalate.
Saquinavir	The metabolism of Debrisoquine can be decreased when combined with Saquinavir.
Secukinumab	The metabolism of Debrisoquine can be increased when combined with Secukinumab.
Selegiline	Selegiline may increase the hypotensive activities of Debrisoquine.
Selexipag	Debrisoquine may increase the hypotensive activities of Selexipag.
Selpercatinib	Selpercatinib may decrease the antihypertensive activities of Debrisoquine.
Serdexmethylphenidate	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Serdexmethylphenidate.
Sertindole	The metabolism of Sertindole can be decreased when combined with Debrisoquine.
Sertraline	The metabolism of Debrisoquine can be decreased when combined with Sertraline.
Sevoflurane	Sevoflurane may decrease the antihypertensive activities of Debrisoquine.
Sildenafil	Sildenafil may increase the antihypertensive activities of Debrisoquine.
Silodosin	The risk or severity of orthostatic hypotension and dizziness can be increased when Debrisoquine is combined with Silodosin.
Siltuximab	The metabolism of Debrisoquine can be increased when combined with Siltuximab.
Simvastatin	The metabolism of Debrisoquine can be decreased when combined with Simvastatin.
Siponimod	Siponimod may decrease the antihypertensive activities of Debrisoquine.
Sitaxentan	Debrisoquine may increase the hypotensive activities of Sitaxentan.
Sodium ferric gluconate complex	The risk or severity of hypotension can be increased when Sodium ferric gluconate complex is combined with Debrisoquine.
Solifenacin	Solifenacin may decrease the antihypertensive activities of Debrisoquine.
Solriamfetol	Solriamfetol may decrease the antihypertensive activities of Debrisoquine.
Sotalol	The metabolism of Sotalol can be decreased when combined with Debrisoquine.
Spirapril	Spirapril may increase the hypotensive activities of Debrisoquine.
Spironolactone	Spironolactone may increase the hypotensive activities of Debrisoquine.
St. John's Wort	The metabolism of Debrisoquine can be decreased when combined with St. John's Wort.
Stiripentol	The metabolism of Debrisoquine can be decreased when combined with Stiripentol.
Streptokinase	Streptokinase may increase the hypotensive activities of Debrisoquine.
Sufentanil	Sufentanil may decrease the antihypertensive activities of Debrisoquine.
Sulfaphenazole	The metabolism of Debrisoquine can be decreased when combined with Sulfaphenazole.
Sulfasalazine	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Sulfasalazine.
Sulindac	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Sulindac.
Sumatriptan	Sumatriptan may decrease the antihypertensive activities of Debrisoquine.
Tadalafil	Tadalafil may increase the hypotensive activities of Debrisoquine.
Tafenoquine	The metabolism of Tafenoquine can be decreased when combined with Debrisoquine.
Tamoxifen	The metabolism of Tamoxifen can be decreased when combined with Debrisoquine.
Tamsulosin	The metabolism of Debrisoquine can be decreased when combined with Tamsulosin.
Tegaserod	The metabolism of Debrisoquine can be decreased when combined with Tegaserod.
Telmisartan	Telmisartan may increase the hypotensive activities of Debrisoquine.
Temsirolimus	The metabolism of Debrisoquine can be decreased when combined with Temsirolimus.
Tenoxicam	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Tenoxicam.
Terazosin	Terazosin may increase the hypotensive activities of Debrisoquine.
Terbinafine	The metabolism of Debrisoquine can be decreased when combined with Terbinafine.
Terbutaline	Terbutaline may decrease the antihypertensive activities of Debrisoquine.
Terfenadine	The metabolism of Debrisoquine can be decreased when combined with Terfenadine.
Tetrabenazine	The metabolism of Tetrabenazine can be decreased when combined with Debrisoquine.
Tetryzoline	Tetryzoline may decrease the antihypertensive activities of Debrisoquine.
Thalidomide	Thalidomide may increase the hypotensive activities of Debrisoquine.
Theophylline	The metabolism of Theophylline can be decreased when combined with Debrisoquine.
Thiopental	Thiopental may increase the hypotensive activities of Debrisoquine.
Thioridazine	The metabolism of Debrisoquine can be decreased when combined with Thioridazine.
Tiaprofenic acid	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Tiaprofenic acid.
Ticlopidine	The metabolism of Debrisoquine can be decreased when combined with Ticlopidine.
Timolol	Timolol may increase the hypotensive activities of Debrisoquine.
Tiotropium	The metabolism of Debrisoquine can be decreased when combined with Tiotropium.
Tipranavir	The metabolism of Debrisoquine can be decreased when combined with Tipranavir.
Tizanidine	Tizanidine may increase the hypotensive activities of Debrisoquine.
Tocilizumab	The metabolism of Debrisoquine can be increased when combined with Tocilizumab.
Tolazoline	Tolazoline may decrease the antihypertensive activities of Debrisoquine.
Tolcapone	Tolcapone may increase the hypotensive activities of Debrisoquine.
Tolfenamic acid	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Tolfenamic acid.
Tolmetin	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Tolmetin.
Tolterodine	The metabolism of Debrisoquine can be decreased when combined with Tolterodine.
Torasemide	Torasemide may increase the hypotensive activities of Debrisoquine.
Trabectedin	The metabolism of Trabectedin can be decreased when combined with Debrisoquine.
Tramadol	The metabolism of Debrisoquine can be decreased when combined with Tramadol.
Trandolapril	Trandolapril may increase the hypotensive activities of Debrisoquine.
Tranylcypromine	The metabolism of Debrisoquine can be decreased when combined with Tranylcypromine.
Trazodone	Trazodone may decrease the antihypertensive activities of Debrisoquine.
Treprostinil	Treprostinil may increase the hypotensive activities of Debrisoquine.
Tretinoin	Tretinoin may decrease the antihypertensive activities of Debrisoquine.
Triamterene	Triamterene may increase the hypotensive activities of Debrisoquine.
Trichlormethiazide	The therapeutic efficacy of Debrisoquine can be increased when used in combination with Trichlormethiazide.
Trichloroethylene	Trichloroethylene may decrease the antihypertensive activities of Debrisoquine.
Triclabendazole	The metabolism of Debrisoquine can be decreased when combined with Triclabendazole.
Trifluoperazine	Trifluoperazine may decrease the antihypertensive activities of Debrisoquine.
Trimethaphan	Trimethaphan may increase the hypotensive activities of Debrisoquine.
Trimipramine	The metabolism of Trimipramine can be decreased when combined with Debrisoquine.
Tripelennamine	The metabolism of Debrisoquine can be decreased when combined with Tripelennamine.
Trospium	The metabolism of Debrisoquine can be decreased when combined with Trospium.
Udenafil	Udenafil may increase the antihypertensive activities of Debrisoquine.
Umeclidinium	The metabolism of Umeclidinium can be decreased when combined with Debrisoquine.
Unoprostone	Debrisoquine may increase the hypotensive activities of Unoprostone.
Valbenazine	The metabolism of Valbenazine can be decreased when combined with Debrisoquine.
Valdecoxib	The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Valdecoxib.
Valsartan	Valsartan may increase the hypotensive activities of Debrisoquine.
Vardenafil	Vardenafil may increase the antihypertensive activities of Debrisoquine.
Vasopressin	Vasopressin may increase the hypertensive activities of Debrisoquine.
Vemurafenib	The metabolism of Debrisoquine can be decreased when combined with Vemurafenib.
Venlafaxine	The metabolism of Debrisoquine can be decreased when combined with Venlafaxine.
Verapamil	The metabolism of Debrisoquine can be decreased when combined with Verapamil.
Vericiguat	Vericiguat may increase the hypotensive activities of Debrisoquine.
Vernakalant	The metabolism of Vernakalant can be decreased when combined with Debrisoquine.
Vilanterol	Vilanterol may decrease the antihypertensive activities of Debrisoquine.
Vilazodone	The metabolism of Debrisoquine can be decreased when combined with Vilazodone.
Viloxazine	The metabolism of Debrisoquine can be decreased when combined with Viloxazine.
Vinblastine	The metabolism of Debrisoquine can be decreased when combined with Vinblastine.
Vinorelbine	The metabolism of Debrisoquine can be decreased when combined with Vinorelbine.
Vortioxetine	Vortioxetine may decrease the antihypertensive activities of Debrisoquine.
Xamoterol	Xamoterol may decrease the antihypertensive activities of Debrisoquine.
Xylometazoline	Xylometazoline may decrease the antihypertensive activities of Debrisoquine.
Yohimbine	Yohimbine may decrease the antihypertensive activities of Debrisoquine.
Ziprasidone	Ziprasidone may increase the antihypertensive activities of Debrisoquine.
Zofenopril	Debrisoquine may increase the hypotensive activities of Zofenopril.
Zolmitriptan	Zolmitriptan may decrease the antihypertensive activities of Debrisoquine.
Zolpidem	The metabolism of Debrisoquine can be decreased when combined with Zolpidem.
Zuclopenthixol	Zuclopenthixol may decrease the antihypertensive activities of Debrisoquine.

Food Interactions

• Take with or without food. The absorption is unaffected by food.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Debrisoquine sulfate	Q94064N9NW	581-88-4	CAYGYVYWRIHZCQ-UHFFFAOYSA-N

International/Other Brands

Bonipress (lkapharm) / Declinax (Roche) / Tendor (Chinoin)

Categories

ATC Codes

C02CC04 — Debrisoquine

• C02CC — Guanidine derivatives
• C02C — ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING
• C02 — ANTIHYPERTENSIVES
• C — CARDIOVASCULAR SYSTEM

Drug Categories

• Adrenergic Agents
• Antiadrenergic Agents, Peripherally Acting
• Antihypertensive Agents
• Autonomic Agents
• Cardiovascular Agents
• Catecholamines
• Cytochrome P-450 CYP2D6 Substrates
• Cytochrome P-450 Substrates
• Guanidine Derivatives
• Heterocyclic Compounds, Fused-Ring
• Isoquinolines
• Neurotransmitter Agents
• P-glycoprotein substrates
• Peripheral Nervous System Agents
• Sympatholytics

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as tetrahydroisoquinolines. These are tetrahydrogenated isoquinoline derivatives.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Tetrahydroisoquinolines

Sub Class

Not Available

Direct Parent

Tetrahydroisoquinolines

Alternative Parents

Benzenoids / Guanidines / Carboximidamides / Azacyclic compounds / Organopnictogen compounds / Imines / Hydrocarbon derivatives

Substituents

Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carboximidamide / Guanidine / Hydrocarbon derivative / Imine / Organic nitrogen compound / Organonitrogen compound / Organopnictogen compound

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

carboxamidine, isoquinolines (CHEBI:34665)

Affected organisms

• Humans and other mammals

Chemical Identifiers

UNII

X31CDK040E

CAS number

1131-64-2

InChI Key

JWPGJSVJDAJRLW-UHFFFAOYSA-N

InChI

InChI=1S/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)

IUPAC Name

1,2,3,4-tetrahydroisoquinoline-2-carboximidamide

SMILES

NC(=N)N1CCC2=CC=CC=C2C1

References

Synthesis Reference

Wenner,W.; U.S. Patent 3,157,573; November 17,1964; assigned to Hoffmann-LaRoche, Inc.

General References

Not Available

External Links

Human Metabolome Database

HMDB0006543

KEGG Compound

C13650

PubChem Compound

2966

PubChem Substance

46507664

ChemSpider

2860

BindingDB

50122613

RxNav

3118

ChEBI

34665

ChEMBL

CHEMBL169901

ZINC

ZINC000003594299

Therapeutic Targets Database

DAP000125

PharmGKB

PA452616

Wikipedia

Debrisoquine

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
Not Available	Unknown Status	Other	Healthy Volunteers (HV)	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Not Available

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	278-280 °C	PhysProp
logP	0.75	SANGSTER (1994)

Predicted Properties

Property	Value	Source
Water Solubility	0.842 mg/mL	ALOGPS
logP	0.58	ALOGPS
logP	1.07	Chemaxon
logS	-2.3	ALOGPS
pKa (Strongest Basic)	12.47	Chemaxon
Physiological Charge	1	Chemaxon
Hydrogen Acceptor Count	3	Chemaxon
Hydrogen Donor Count	2	Chemaxon
Polar Surface Area	53.11 Å2	Chemaxon
Rotatable Bond Count	0	Chemaxon
Refractivity	63.85 m3·mol-1	Chemaxon
Polarizability	19.48 Å3	Chemaxon
Number of Rings	2	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.9714
Blood Brain Barrier	+	0.9106
Caco-2 permeable	+	0.5
P-glycoprotein substrate	Substrate	0.8427
P-glycoprotein inhibitor I	Non-inhibitor	0.8781
P-glycoprotein inhibitor II	Non-inhibitor	0.8382
Renal organic cation transporter	Inhibitor	0.8817
CYP450 2C9 substrate	Non-substrate	0.8429
CYP450 2D6 substrate	Substrate	0.8918
CYP450 3A4 substrate	Non-substrate	0.7101
CYP450 1A2 substrate	Non-inhibitor	0.9045
CYP450 2C9 inhibitor	Non-inhibitor	0.9549
CYP450 2D6 inhibitor	Non-inhibitor	0.9231
CYP450 2C19 inhibitor	Non-inhibitor	0.9026
CYP450 3A4 inhibitor	Non-inhibitor	0.9532
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9462
Ames test	Non AMES toxic	0.7018
Carcinogenicity	Non-carcinogens	0.976
Biodegradation	Not ready biodegradable	0.9422
Rat acute toxicity	2.7479 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.6904
hERG inhibition (predictor II)	Inhibitor	0.5928

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	splash10-0ue9-2900000000-5f2dcf1ab6da5e83a08a
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-004i-0900000000-5deb90f73bb93308cff7
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-001i-2900000000-aec4221b654ddee5d07f
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-001i-0900000000-8219978c5f92fed50beb
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-00kf-6900000000-198ab5c9c978861573ca
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-001i-0900000000-33463e1195da20620136
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-001l-5900000000-11cf232d32ce02e4ccd0
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å2)	Source type	Source
[M-H]-	141.5480292	predicted	DarkChem Lite v0.1.0
[M-H]-	135.38689	predicted	DeepCCS 1.0 (2019)
[M+H]+	143.1160292	predicted	DarkChem Lite v0.1.0
[M+H]+	138.13324	predicted	DeepCCS 1.0 (2019)
[M+Na]+	141.6097292	predicted	DarkChem Lite v0.1.0
[M+Na]+	147.29137	predicted	DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. Sodium-dependent noradrenaline transporter

Kind

Protein

Organism

Humans

Pharmacological action

Yes

Actions

Inducer

General Function

Norepinephrine:sodium symporter activity

Specific Function

Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.

Gene Name

SLC6A2

Uniprot ID

P23975

Uniprot Name

Sodium-dependent noradrenaline transporter

Molecular Weight

69331.42 Da

References

1. Joyce PI, Rizzi D, Calo G, Rowbotham DJ, Lambert DG: The effect of guanethidine and local anesthetics on the electrically stimulated mouse vas deferens. Anesth Analg. 2002 Nov;95(5):1339-43, table of contents. [Article]
2. Bryan-Lluka LJ, Seers H, Sharpe I: Amezinium and debrisoquine are substrates of uptake1 and potent inhibitors of monoamine oxidase in perfused lungs of rats. Naunyn Schmiedebergs Arch Pharmacol. 1996 Apr;353(5):536-44. [Article]
3. Mitchell JR, Cavanaugh JH, Arias L, Oates JA: Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man. J Clin Invest. 1970 Aug;49(8):1596-604. [Article]
4. Yi E, Love JA: Alpha-adrenergic modulation of synaptic transmission in rabbit pancreatic ganglia. Auton Neurosci. 2005 Oct 30;122(1-2):45-57. Epub 2005 Aug 25. [Article]
5. Galli A, Blakely RD, DeFelice LJ: Norepinephrine transporters have channel modes of conduction. Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8671-6. [Article]

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at September 26, 2007 15:28 / Updated at April 09, 2024 18:25